Gyroscope is committed to changing ophthalmology and fighting the devastating impact of sight loss

It is exploiting the convergence of breakthroughs in genetics and proprietary insights into the role of the complement system in AMD to develop a series of one-off gene therapy treatments for dry AMD and other chronic eye diseases.

The company was founded in 2016 with investments from Syncona and Cambridge Enterprise. Gyroscope is located in Stevenage at the Bioscience Catalyst.